ABINGTON, Mass. and VANCOUVER, BC, July 30, 2026 /PRNewswire/ — The FSHD Society, SOLVE FSHD, and the FSHD Clinical Trial Research Network (FSHD CTRN) today announced significant momentum for the FSHD Industry Collaborative, including the addition of four new biopharma sponsors and meaningful early progress across all active research workstreams. Launched in April 2026, the …
The FSHD Industry Collaborative is a first-of-its-kind, multi-stakeholder initiative designed to improve how FSHD clinical trials are designed, executed, and evaluated RANDOLPH, Mass. and VANCOUVER, BC, April 8, 2026 /PRNewswire/ — The FSHD Society, a patient-driven organization advancing research and clinical development in facioscapulohumeral muscular dystrophy (FSHD), SOLVE FSHD, a venture philanthropic organization dedicated to accelerating treatments …
VANCOUVER, British Columbia–(BUSINESS WIRE)–SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), today announced grant funding awarded following its 2025 Request for Proposals. SOLVE FSHD will provide funding to leading clinician scientists validating biomarker assays and clinical outcome frameworks in FSHD, with the intent to share the results with the …
Interim data demonstrated a favorable safety profile and early evidence of disease modification, including statistically significant increases in lean muscle volume and biomarker changes consistent with DUX4 suppression Additional clinical data expected to be presented at the World Muscle Society Annual Congress in September 2026 SAN FRANCISCO–(BUSINESS WIRE)–Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, …
Single-Dose EPI-321 Demonstrated a Positive Safety Profile and Increased Lean Muscle Volume Across the First Three Evaluable Patients at Six MonthsEPI-321 is the First Investigational Therapy Designed to Silence DUX4, the Genetic Driver of FSHD SAN FRANCISCO, CA – June 26, 2026 – Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim data …
GAITHERSBURG, Md.–(BUSINESS WIRE)–Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration focuses on delivering transformative treatments for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). Building upon the companies’ successful partnership in developing ARC therapies, the expanded agreement will facilitate …